MS
ZBIO

Maven Securities’s Zenas BioPharma ZBIO Stock Holding History

Maven Securities’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-150,000
Closed -$2.93M – 488
2026
Q1 		$2.93M Buy
+150,000
New +$3.37M 0.06% 234
2024
Q4 		– Sell
-31,054
Closed -$525K – 1055
2024
Q3 		$525K Buy
+31,054
New +$558K 0.01% 638

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Maven Securities's ZBIO Position: Q2 2026 in Review

Maven Securities sold out of Zenas BioPharma (ZBIO) in Q2 2026, closing a stake of 150,000 shares — an estimated $2.93M sold.

Maven Securities first reported a position in ZBIO in Q3 2024 and held it in 2 quarters. The position peaked at $2.93M in Q1 2026. 145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Maven Securities reported no remaining Zenas BioPharma position as of Q2 2026 after selling out during the quarter.
  • Maven Securities sold 150,000 Zenas BioPharma shares in Q2 2026, an estimated $2.93M.
  • Maven Securities first reported a position in Zenas BioPharma in Q3 2024 and held it in 2 quarters.
  • Maven Securities's Zenas BioPharma position peaked at $2.93M in Q1 2026.
  • 145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Maven Securities's 13F filing for Q2 2026, filed 14 Aug 2026.